{"generic":"Eletriptan Hydrobromide","drugs":["Eletriptan Hydrobromide","Relpax"],"mono":{"0":{"id":"jvsus0","title":"Generic Names","mono":"Eletriptan Hydrobromide"},"1":{"id":"jvsus1","title":"Dosing and Indications","sub":[{"id":"jvsus1b4","title":"Adult Dosing","mono":"<b>Migraine (Acute):<\/b> initial, 20 or 40 mg ORALLY; may repeat after 2 hours if migraine returns\/persists; MAX single dose: 40 mg; MAX daily dose: 80 mg "},{"id":"jvsus1b5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},{"id":"jvsus1b6","title":"Dose Adjustments","mono":"<ul><li><b>hepatic impairment, severe:<\/b> use not recommended<\/li><li><b>hepatic impairment, mild to moderate:<\/b> no dosage adjustment necessary<\/li><\/ul>"},{"id":"jvsus1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Migraine (Acute)<br\/>"}]},"3":{"id":"jvsus3","title":"Contraindications\/Warnings","sub":[{"id":"jvsus3b9","title":"Contraindications","mono":"<ul><li>coronary artery vasospasm, including Prinzmetal angina<\/li><li>CYP3A4 inhibitors, potent (ie, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir); concomitant or recent use (ie, within 72 hours)<\/li><li>ergotamine-containing or ergot-type agents such as dihydroergotamine or methysergide; concomitant or recent use (ie, within 24 hours)<\/li><li>5-hydroxytryptamine-1 agonists; concomitant or recent use (ie, within 24 hours)<\/li><li>hypersensitivity to eletriptan<\/li><li>hemiplegic or basilar migraine, current or history; increased risk for stroke<\/li><li>hypertension, uncontrolled<\/li><li>ischemic bowel disease<\/li><li>ischemic coronary artery disease (eg, confirmed silent ischemia, angina pectoris, history of myocardial infarction)<\/li><li>peripheral vascular disease<\/li><li>stroke or TIA, history of; increased risk for stroke<\/li><li>Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders<\/li><\/ul>"},{"id":"jvsus3b10","title":"Precautions","mono":"<ul><li>arrhythmia, (eg, ventricular tachycardia, ventricular fibrillation) including fatalities, has been reported within hours of use of 5-hydroxytryptamine-1 agonists; discontinue if occurs<\/li><li>blood pressure elevation, significant including hypertensive crisis with acute impairment of organ systems, has been reported in patients with or without a history of hypertension after use of 5-hydroxytryptamine-1 agonists; monitoring recommended<\/li><li>coronary artery vasospasm (Prinzmetal's angina) may occur in patients with or without a history of coronary artery disease; monitoring recommended in patients at risk<\/li><li>cardiac events, serious including acute myocardial infarction and fatalities, have been reported within a few hours of administration in patients with or without known coronary artery disease; consider administration of first dose in a medically supervised setting in triptan-naive patients with multiple cardiovascular risk factors, or in patients at risk who have a negative cardiovascular evaluation and perform ECG immediately after administration; periodic monitoring recommended, particularly with long-term intermittent use<\/li><li>cerebrovascular events (eg, cerebral hemorrhage, subarachnoid hemorrhage, stroke), some fatal, have been reported with the use of 5-hydroxytryptamine-1 agonists; exclude other serious neurologic conditions prior to initiating therapy in non-migraineurs and in migraineurs presenting with atypical migraine symptoms<\/li><li>coronary artery vasospasm (Prinzmetal angina) may occur in patients with or without history of coronary artery disease; consider administration of first dose in a medically supervised setting in triptan-naive patients with multiple cardiovascular risk factors or in patients at risk who have a negative cardiovascular evaluation and perform ECG immediately after administration; periodic monitoring recommended, particularly with  long-term intermittent use<\/li><li>hepatic impairment, severe; use not recommended<\/li><li>hypersensitivity reactions, including anaphylaxis, anaphylactoid, and angioedema, have occurred; increased risk in patients with history of multiple allergies<\/li><li>medication overuse headache may occur when acute migraine drugs are used for 10 or more days per month; detoxification and treatment of withdrawal symptoms may be necessary<\/li><li>pain, tightness, heaviness, or pressure sensations in the chest, throat, neck, or jaw (non-cardiac-related), have been reported; cardiac evaluation recommended in patients with high cardiac risk; discontinue use if occurs<\/li><li>serotonin syndrome may occur within minutes to hours of new or increased doses of serotonergic drugs, particularly with concomitant use of SSRIs, serotonin norepinephrine reuptake inhibitors, tricyclic antidepressants, or MAOIs; discontinue use if suspected<\/li><li>vasospastic reactions, non-coronary related (eg, Raynaud syndrome, peripheral vascular ischemia, gastrointestinal vascular ischemia and infarction) may occur; if symptoms are observed, rule out vasospastic reaction prior to administering additional doses<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"jvsus3b11","title":"Pregnancy Category","mono":"<ul><li>Eletriptan: C (FDA)<\/li><li>Eletriptan: B1 (AUS)<\/li><\/ul>"},{"id":"jvsus3b12","title":"Breast Feeding","mono":"Eletriptan: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jvsus4","title":"Drug Interactions","sub":[{"id":"jvsus4b13","title":"Contraindicated","mono":"<ul><li>Almotriptan (theoretical)<\/li><li>Amprenavir (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Bromocriptine (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Delavirdine (theoretical)<\/li><li>Dihydroergotamine (theoretical)<\/li><li>Ergonovine (theoretical)<\/li><li>Ergotamine (theoretical)<\/li><li>Fosamprenavir (theoretical)<\/li><li>Frovatriptan (probable)<\/li><li>Imatinib (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ketoconazole (probable)<\/li><li>Linezolid (theoretical)<\/li><li>Lomitapide (theoretical)<\/li><li>Methylergonovine (theoretical)<\/li><li>Methysergide (theoretical)<\/li><li>Miconazole (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Naratriptan (theoretical)<\/li><li>Nefazodone (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Regorafenib (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Rizatriptan (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sumatriptan (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Ticagrelor (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><li>Troleandomycin (theoretical)<\/li><li>Zolmitriptan (theoretical)<\/li><\/ul>"},{"id":"jvsus4b14","title":"Major","mono":"<ul><li>Amiodarone (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amoxapine (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Desvenlafaxine (theoretical)<\/li><li>Dolasetron (theoretical)<\/li><li>Duloxetine (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Fentanyl (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Fluvoxamine (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Hydroxytryptophan (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Lorcaserin (theoretical)<\/li><li>Meperidine (theoretical)<\/li><li>Milnacipran (theoretical)<\/li><li>Mirtazapine (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Palonosetron (theoretical)<\/li><li>Paroxetine (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Reboxetine (theoretical)<\/li><li>Sertraline (theoretical)<\/li><li>Sibutramine (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>St John's Wort (probable)<\/li><li>Tapentadol (theoretical)<\/li><li>Tramadol (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Venlafaxine (theoretical)<\/li><li>Vilazodone (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Vortioxetine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"}]},"5":{"id":"jvsus5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Nausea (Up to 8%)<\/li><li><b>Neurologic:<\/b>Asthenia (4% to 10%), Somnolence (3% to 7%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Chest pain (Up to 4%), Coronary artery spasm, Myocardial infarction, Transient myocardial ischemia<\/li><li><b>Immunologic:<\/b>Anaphylactoid reaction, Anaphylaxis, Hypersensitivity reaction<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident, Seizure<\/li><li><b>Other:<\/b>Serotonin syndrome<\/li><\/ul>"},"6":{"id":"jvsus6","title":"Drug Name Info","sub":{"0":{"id":"jvsus6b17","title":"US Trade Names","mono":"Relpax<br\/>"},"2":{"id":"jvsus6b19","title":"Class","mono":"<ul><li>Antimigraine<\/li><li>Serotonin Receptor Agonist, 5-HT1<\/li><\/ul>"},"3":{"id":"jvsus6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jvsus6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jvsus7","title":"Mechanism Of Action","mono":"Eletriptan has high affinity for 5-HT1 receptor subtypes, more specifically those receptors located on intracranial blood vessels, and acts as a receptor agonist at those sites. Two theories exist to explain the 5-HT1 receptor agonists in migraine headaches: activation of 5-HT1 vasoconstricts intracranial blood vessels and correlates to relief of migraine headaches; activation of 5-HT1 receptors on sensory nerve endings  inhibits pro-inflammatory response in the trigeminal system.<br\/>"},"8":{"id":"jvsus8","title":"Pharmacokinetics","sub":[{"id":"jvsus8b23","title":"Absorption","mono":"<ul><li>Oral, tablets: time to peak concentration, 2 h<\/li><li>Bioavailability: (Oral), approximately 50%<\/li><li>Effect of food: (Oral), the area under the concentration-time curve (AUC), and maximum concentration (Cmax) are increased 20% to 30% after a high fat meal<\/li><\/ul>"},{"id":"jvsus8b24","title":"Distribution","mono":"<ul><li>Vd: 138 L<\/li><li>Protein binding: moderate, 85%<\/li><\/ul>"},{"id":"jvsus8b25","title":"Metabolism","mono":"<ul><li>Hepatic; isoenzyme P450 CYP3A4<\/li><li>Active metabolites: N-demethylated metabolite; 10% to 20% plasma concentration of eletriptan<\/li><\/ul>"},{"id":"jvsus8b26","title":"Excretion","mono":"<ul><li>Non-renal: 90%<\/li><li>Dialyzable: unknown (hemodialysis); unknown (peritoneal)<\/li><\/ul>"},{"id":"jvsus8b27","title":"Elimination Half Life","mono":"<ul><li>Eletriptan: (normal population) 4 h<\/li><li>Eletriptan: (elderly) 4.4 h to 5.7 h<\/li><li>Eletriptan: (hepatic impairment) increase in half-life<\/li><li>N-demethylated metabolite: 13 h<\/li><\/ul>"}]},"9":{"id":"jvsus9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>administer first dose in medically-supervised setting for patients with multiple cardiovascular risk factors<\/li><li>do not administer within 24 hours of any ergotamine-containing medication, ergot-type medication, or any other 5-hydroxytryptamine-1 (5-HT1) agonist<\/li><li>do not administer within 72 hours of potent CYP3A4 inhibitors including ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir.<\/li><\/ul>"},"10":{"id":"jvsus10","title":"Monitoring","mono":"<ul><li>relief of headache and associated symptoms is indicative of efficacy<\/li><li>cardiovascular (CV) evaluation; prior to treatment initiation in elderly, at-risk, or triptan-naive patients with multiple CV risk factors to rule out coronary artery disease or vasospasm; if treatment is initiated, consider ECG upon first use and periodic CV evaluations in long-term intermittent users of eletriptan or in patients with high cardiac-risk who experience vasospasm following administration<\/li><li>neurological evaluation; before treatment initiation in patients previously undiagnosed or presenting with atypical symptoms<\/li><li>blood pressure; during therapy<\/li><\/ul>"},"11":{"id":"jvsus11","title":"How Supplied","mono":"<b>Relpax<\/b><br\/>Oral Tablet: 20 MG, 40 MG<br\/>"},"13":{"id":"jvsus13","title":"Clinical Teaching","mono":"<ul><li>Tell patient this drug only treats migraines and will not prevent migraines from occurring.<\/li><li>Patient should avoid activities requiring mental alertness or coordination until drug effects are realized, as this drug may cause dizziness or somnolence.<\/li><li>This drug may cause nausea or asthenia.<\/li><li>Instruct patient to immediately report signs\/symptoms of ischemic cardiac syndrome (eg, angina, myocardial infarction, stroke, or TIA).<\/li><li>Advise patient to immediately report signs\/symptoms of ischemic bowel disease (eg, sudden severe abdominal pain, bloody diarrhea) or peripheral vascular disease (eg, Raynaud syndrome).<\/li><li>Instruct patient to immediately report signs\/symptoms of serotonin syndrome (eg, agitation, hallucinations, tachycardia, hyperthermia, labile blood pressure, hyperreflexia, incoordination, diarrhea, nausea and vomiting).<\/li><li>Advise patient to immediately report signs\/symptoms of hypertensive crisis.<\/li><li>Instruct patient to take a second dose 2 or more hours after the first, if needed, and no more than 80 mg a day.<\/li><li>Patient should avoid taking drug within 24 hours of ergotamine-containing medications (eg, dihydroergotamine), ergot-type medications (eg, methysergide), or 5-HT1 agonists.<\/li><li>Patient should avoid taking drug within 72 hours of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir).<\/li><\/ul>"}}}